A focused approach to biotechnology investing
BB Biotech is one of the world’s most established biotech investors, offering concentrated exposure to companies developing the next generation of medicines.
Pure biotech focus
BB Biotech focuses on biotechnology innovation, avoiding broad healthcare exposure. This focus enables deeper expertise, higher conviction and a clear investment profile.
Active, high-conviction
A concentrated portfolio of selected biotech companies across large, mid and small caps. Built to capture upside from innovation while actively managing risk.
Access & expertise
Direct access to leading and emerging biotechnology companies worldwide, backed by a highly experienced investment team with deep scientific expertise and a long-standing track record across market cycles.
Disciplined capital for breakthrough biotechnology
Since 1993, BB Biotech has provided investors with direct access to a carefully selected portfolio of biotechnology companies worldwide, built on deep scientific expertise and long-term investment experience.
Rather than tracking an index, BB Biotech allocates capital with conviction, focusing on differentiated innovation, strong development pipelines and disciplined capital management to support long-term medical and economic value creation.
Strategic positioning for 2026
The biotechnology sector has demonstrated remarkable resilience. Fundamental progress across the industry remains strong, supported by a steady flow of positive clinical readouts and new product approvals. Innovation continues to translate into tangible value, even against a challenging macro backdrop.
Looking into 2026, the opportunity set remains compelling. Capital discipline across the sector has sharpened, pipelines are more focused, and large pharmaceutical companies face increasing pressure to replenish growth through innovation. This environment favours companies with differentiated science, clear development.
Concentrated exposure to biotech innovation, guided by discipline and conviction.
A changing biotech landscape is creating new opportunities
The biotech industry is entering a new phase.
The biotechnology industry is entering a new phase. Large pharmaceutical companies face a significant patent cliff and increasingly rely on external innovation to sustain future growth.
At the same time, reimbursement is becoming more selective, favouring truly differentiated therapies with clear medical value. This environment rewards companies with strong science, advanced pipelines and scalable platforms. BB Biotech is positioned to benefit from these structural shifts.
Why biotech, why now
Growing demand for innovative therapies addressing unmet medical needs
A significant patent cliff accelerating M&A and innovation demand
A key driver of medical innovation, particularly in oncology, rare diseases and genetic medicine.
Identify innovation
Focus on differentiated innovation addressing high unmet medical needs.
Deep diligence
In-depth scientific, clinical and financial diligence, supported by data-driven analysis.
Selection
Only ideas meeting strict return and risk criteria enter a concentrated portfolio.
Active ownership
Positions are actively managed and adjusted as scientific, clinical and valuation data evolves.
"We invest in companies improving patient outcomes."
Thomas von Planta
Chairman
30+ years of focused biotech investing
One of Europe’s leading listed biotech investors
Portfolio of ~20–35 companies
Long-term, conviction-driven capital growth
What to expect
as an investor
Access to a fast-growing, highly dynamic market with strong structural growth drivers via a concentrated portfolio.
Potential to benefit from breakthrough drugs, successful clinical milestones, and strategic M&A activity.
Active management to capture value as scientific and commercial expectations evolve.